From Eindhoven University of Technology (TU/e) and the Radboud University Medical Center (Radboudumc) present BIOTRIP. BIOTRIP is a unique platform that brings together medical scientists and enterprising biomedical engineers to work with biotech entrepreneurs to develop, commercialize and make vaccines and immunotherapies available for patients with a variety of diseases.
Solution-oriented
BIOTRIP is a unique initiative between two top institutes in the south of the Netherlands. “If the Covid-19 pandemic has taught us anything, it is that merging biomedical technology and clinical research leads to innovative solutions. BIOTRIP will generate technologies and commercial opportunities that will contribute to solving the medical problems of the future,” says TU/e Rector Frank Baaijens. For example, BIOTRIP is developing a universal vaccine to elicit broad protection in the population against emerging SARS-CoV-2 variants and potential future pandemics.
Sign up for IO on Telegram!
Sign In!
—
“BIOTRIP is a flexible and biotech investor-oriented incubator with which we want to realize new biotech startups in the Brainport region. The south of the Netherlands secretly houses a fantastic biotech ecosystem, in which BIOTRIP fits in very well and will ensure growth and innovation”, explains the chairman of the Executive Board of the TU/e, Robert-Jan Smits.
Special collaboration
BIOTRIP has brought together an exceptional team of entrepreneurial academics, biotech professionals and an internationally oriented group of advisors. “We are extremely grateful for the participation of Dr. John Kastelein and Dr. Andrea van Elsas in this special venture. Both are highly successful biotech entrepreneurs, John operating from the Netherlands and Andrea was hired last year as a partner at Third Rock Ventures on the west coast of the United States,” said BIOTRIP co-founder Dr. William Mulder. The other co-founder Dr. Mihai Netea added: “We are really looking forward to working with Dr. Alexander Eggermont. dr. Eggermont is Chief Scientific Officer of the Princes Máxima Center for Pediatric Oncology and a renowned clinical researcher in cancer immunotherapy.”
In addition, BIOTRIP also consists of external advisors Dr. Cristianne Rijcken, Chief Scientific Officer and founder of Cristal Therapeutics, and Thomas Sehested, three-time windsurfing world champion and serial entrepreneur. with drs. Zahi Fayad and Matthias Nahrendorf, institute professors at respectively Icahn School of Medicine at Mount Sinai on Massachusetts General Hospital, the external advisory board is complete.
Using knowledge for patients
“BIOTRIP is one of the most exciting initiatives I’ve worked on. With a team of immunotherapy pioneers and highly creative biomedical engineers, we are working on solutions for various disorders, such as cancer, autoimmune, infectious and cardiovascular diseases, as well as organ transplantation”, responds BIOTRIP quartermaster Dr. Joost Kreijtz.
dr. Bertine Lahuis, chairman of the board of Radboudumc, is enthusiastic: “Over the past ten years, the work of our clinical researchers has provided unique insights into the human immune system. Now is the time to use this knowledge for our patients.” Dean Dr. Jan Smit concludes: “With BIOTRIP we are concretising our biotech ambitions through a formal alliance with TU/e. We are convinced that BIOTRIP will deliver new innovations that will improve the quality of life for patients worldwide.”
–
